Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: An analysis from the SHIFT trial

European Journal of Heart Failure

Volumn 17, Issue 12, 2015, Pages 1294-1301

  Komajda, Michel ^a   Tavazzi, Luigi ^b   Francq, Bernard G ^c   Böhm, Michael ^d   Borer, Jeffrey S ^e   Ford, Ian ^c   Swedberg, Karl ^f,g  

^a SORBONNE UNIVERSITÉ   (France)

^b Research Ettore Sansavini Health Science Foundation   (Italy)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SAARLAND UNIVERSITY   (Germany)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Diabetes mellitus; Insulin; Ischaemic heart failure; Ivabradine; Severe heart failure

Indexed keywords

INSULIN; IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLURRED VISION; BRADYCARDIA; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; COMPLICATION; CONTROLLED STUDY; HEART FAILURE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BENZAZEPINES; CARDIOVASCULAR AGENTS; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84949538360     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.347     Document Type: Article

References (33)

1. Baliga V, Sapsford R,. Review article: Diabetes mellitus and heart failure-an overview of epidemiology and management. Diab Vasc Dis Res 2009; 6: 164-171.
2. Kamalesh M, Cleophas TJ,. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. J Card Fail 2009; 15: 305-309.
3. Cohen-Solal A, Beauvais F, Logeart D,. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008; 14: 615-625.
4. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, Maggioni AP, Voors AA,. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103-111.
5. Macdonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ,. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-1240.
6. Dei CA, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC,. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015; 3: 136-145.
7. Sharma A, Ezekowitz JA,. Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar. Eur J Heart Fail 2014; 16: 1153-1156.
8. Khan SS, Butler J, Gheorghiade M,. Management of comorbid diabetes mellitus and worsening heart failure. JAMA 2014; 311: 2379-2380.
9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
10. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC,. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-1637.
11. Dei Cas A, Fonarow GC, Gheorghiade M, Butler J,. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol 2015 Jan; 40 (1): 7-43. Epub ahead of print. Available at: 10.1016/j.cpcardiol.2014.09.002.
12. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875-885.
13. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L,. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010; 12: 75-81.
14. Kotler MN, Berman L, Rubenstein AH,. Hypoglycaemia precipitated by propranolol. Lancet 1966; 2: 1389-1390.
15. Ostman J, Asplund K, Bystedt T, Dahlof B, Jern S, Kjellstrom T, Lithell H,. Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. J Intern Med 1998; 244: 95-107.
16. Pollare T, Lithell H, Selinus I, Berne C,. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-1157.
17. Anselmino M, Ohrvik J, Ryden L,. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart. Eur Heart J 2010; 31: 3040-3045.
18. Hillis GS, Hata J, Woodward M, Perkovic V, Arima H, Chow CK, Zoungas S, Patel A, Poulter NR, Mancia G, Williams B, Chalmers J,. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc 2012; 1:e002832-
19. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A,. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004; 308: 236-240.
20. Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Bohm M,. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-1985.
21. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De BG, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG,. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087.
22. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner SL,. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
23. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J,. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159-167.
24. Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
25. Smooke S, Horwich TB, Fonarow GC,. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168-174.
26. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ,. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38: 421-428.
27. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC,. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-1020.
28. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR,. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914-922.
29. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S,. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116: 300-304.
30. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, Torp-Pedersen C,. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43: 771-777.
31. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB,. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65-75.
32. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
33. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM,. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590.